Rakovina Therapeutics International Bond
RKV Stock | CAD 0.1 0.01 18.75% |
Net Debt is likely to drop to about 717.4 K in 2024. Long Term Debt is likely to drop to about 1.1 M in 2024. Rakovina Therapeutics' financial risk is the risk to Rakovina Therapeutics stockholders that is caused by an increase in debt.
At this time, Rakovina Therapeutics' Non Current Liabilities Total is fairly stable compared to the past year. Change To Liabilities is likely to climb to about 47.9 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 103.3 K in 2024. Rakovina |
Given the importance of Rakovina Therapeutics' capital structure, the first step in the capital decision process is for the management of Rakovina Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Rakovina Therapeutics to issue bonds at a reasonable cost.
Popular Name | Rakovina Therapeutics International Game Technology |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | CA75103L1013 |
Bond Issue ISIN Code | US460599AD57 |
S&P Rating | Others |
Maturity Date | 15th of January 2027 |
Issuance Date | 26th of September 2018 |
Coupon | 6.25 % |
Rakovina Therapeutics Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
International Game Technology | US460599AD57 | Details | |
BNP Paribas FRN | USF1R15XK367 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
AerCap Global Aviation | US00773HAA59 | Details |
Understaning Rakovina Therapeutics Use of Financial Leverage
Understanding the structure of Rakovina Therapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Rakovina Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | 807.1 K | 717.4 K | |
Long Term Debt | 1.2 M | 1.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.